Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib
- 1 January 2007
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 43 (1), 55-63
- https://doi.org/10.1016/j.ejca.2006.08.032
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid TumorsClinical Cancer Research, 2005
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnnals of Oncology, 2005
- Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid TumorsJournal of Clinical Oncology, 2005
- Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2004
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid CarcinomasJournal of Clinical Endocrinology & Metabolism, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- BAY 43-9006: Preclinical DataCurrent Pharmaceutical Design, 2002
- The role of Raf kinases in malignant transformationExpert Reviews in Molecular Medicine, 2002
- Involvement of platelet-derived growth factor in disease: development of specific antagonistsAdvances in Cancer Research, 2001